Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor.
Dental extraction in patients with haemophilia A and high-titre inhibitor is always a high-risk procedure, which often presents a lot of problems associated with bleeding. Prothrombin complex concentrates or recombinant activated factor VII (rFVIIa) has been used to control bleeding. rFVIIa was administered to five boys with severe haemophilia A complicated with inhibitor, who underwent seven dental extractions. The age of the patients ranged between 8 and 13 years (median 10 years). The concentrate was administered in doses of 90-100 microg kg(-1) body weight. Duration in the therapy and intervals between rFVIIa doses depended on the severity of bleeding. rFVIIa was proven to be highly effective and no side-effects of the product were observed.
Laguna
P
P
Department of Paediatrics, Haematology, and Oncology, Warsaw Medical University, Poland. skazy@littewska.edu.pl
Klukowska
A
A
D019774:Blood Coagulation Factor Inhibitors / Q000032:analysis; D002648:Child; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006467:Hemophilia A / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006488:Hemostasis, Surgical; D006801:Humans; D008297:Male; D006472:Oral Hemorrhage / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014081:Tooth Extraction / Q000009:adverse effects
D019774:Blood Coagulation Factor Inhibitors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa